Sunday 31 January 2016
  • :
  • :

Pre-Market News Report on: Yelp (NYSE:YELP), Boeing (NYSE:BA), Oncothyreon (NASDAQ:ONTY), Akamai Technologies, (NASDAQ:AKAM)

On Tuesday, Yelp Inc (NYSE:YELP)’s shares declined -0.50% to $45.44.

Blue Calypso, Inc. developer of patented mobile consumer shopping engagement solutions for retailers and product manufacturers, recently declared the Court has reset a Claim Construction Hearing, or “Markman hearing” for July 8, 2015 in the Eastern District of Texas for Blue Calypso’s patent infringement lawsuits against Groupon , Foursquare, Yelp (YELP) and IZEA. The hearing had been planned for Jun 29, 2015. Judge Rodney Gilstrap will preside.

Yelp Inc. operates a platform that connects people with local businesses in the United States. Its platform covers various local business categories, counting restaurants, shopping, beauty and fitness, arts, entertainment and events, home and local services, health, nightlife, travel and hotel, auto, and others categories.

Boeing Co (NYSE:BA)’s shares dropped -0.40% to $140.08.

Boeing Co (BA) released its 2015 Environment Report highlighting the company’s raised use of renewable energy, testing of environmentally promising technologies and other progress toward improving the environmental performance of its products, services and operations.

Highlights of the 2015 Report comprise:

  • Increasing use of renewable energy, counting powering the 4.3-million-square-foot 737 factory in Renton, Washington, with electricity from 100-percent renewable sources.
  • Testing more than 40 technologies on the ecoDemonstrator 787 and 757 to improve airplane fuel efficiency and reduce emissions and noise.
  • Ongoing Boeing leadership to develop sustainable aviation biofuel, counting the world’s first flights using “green diesel”.
  • Successfully launching the first two all-electric-propulsion satellites, which use only clean electric power and nonhazardous gas for propulsion.
  • Collaborating with global partners on environmental issues facing the aerospace industry
  • Feature stories on employees around the world who are working to improve Boeing’s environmental performance.

The Boeing Company, together with its auxiliaries, designs, develops, manufactures, sells, services, and supports commercial jetliners, military aircraft, satellites, missile defense, human space flight, and launch systems and services worldwide. The company operates in five segments: Commercial Airplanes, Boeing Military Aircraft, Network & Space Systems, Global Services & Support, and Boeing Capital.

At the end of Tuesday’s trade, Oncothyreon Inc (USA) (NASDAQ:ONTY)‘s shares dipped -3.19% to $3.95.

Oncothyreon Inc. (ONTY) recently declared the presentation of positive data from the company’s ongoing trials of ONT-380, an orally active, reversible and selective small-molecule HER2 inhibitor for the treatment of breast cancer, at the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting. The first presentation updated data from the Phase 1b trial of ONT-380 in combination with Xeloda(R) (capecitabine)and Herceptin(R) (trastuzumab) in third line treatment of HER2-positive metastatic breast cancer. The data support Oncothyreon’s plans to initiate a blinded, randomized, placebo-controlled Phase 2 trial in this indication. The second presentation focused on the role of ONT-380 in the treatment of HER2-positive breast cancer central nervous system (CNS) metastases.

Patients comprised of in the presentation on the role of ONT-380 in the treatment of CNS metastases were selected from the above trial and from an ongoing Phase 1b trial ( Identifier NCT01983501) of ONT-380 in combination with Kadcyla in patients who have been formerly treated with Herceptin and a taxane for metastatic breast cancer. Patients were comprised of if their presenting CNS lesions were evaluable for response using RECIST 1.1 criteria and they had either untreated, asymptomatic lesions having never received radiotherapy or surgery to the CNS (n=8) or new or progressive lesions following prior CNS therapy (n=14). Best CNS response was a CR in one patient, a PR in four patients and SD in nine patients. No patient had progressive disease as a CNS best response. One patient was not evaluable for response having undergone surgery for a symptomatic CNS lesion; pathologic examination of the resected specimen found no evidence of viable tumor. Two patients were not evaluated because of progressive disease outside of the CNS, while five patients in the series remain too early to evaluate.

Oncothyreon Inc., a clinical-stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of cancer. Its clinical-stage product candidates comprise ONT-380, an orally active and selective small-molecule HER2 inhibitor, which is in two Phase 1b trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin; and ONT-10, a therapeutic vaccine in Phase 1 trial targeting the Mucin 1 peptide antigen (MUC1) for use in various cancer indications, counting breast, thyroid, colon, stomach, pancreas, ovarian, and prostate, in addition to certain types of lung cancer.

Akamai Technologies, Inc. (NASDAQ:AKAM), ended its Tuesday’s trading session with -2.66% loss, and closed at $72.90.

Akamai Technologies, Inc. (AKAM) has inked a partnership deal with China Unicom’s cloud business, CU Cloud, to offers its full range of web performance, media delivery, and cloud security services.

One of China’s largest cloud computing service providers, CU Cloud will bundle its services with Akamai’s offerings and both partners will further develop opportunities aimed at assisting Chinese businesses expand their web presence globally.

Akamai said the deal would extend the reach of its CDN (content delivery network) services in China. It added that CU Cloud also would be tapping its “turnkey CDN” technology to deliver its own cloud services.

Akamai Technologies, Inc. provides cloud services for delivering, optimizing, and securing online content and business applications in the United States and internationally. The company offers media content delivery solutions to execute digital media distribution strategies, counting download delivery solutions for the distribution of file downloads, such as games, progressive video and audio files, documents, and other file-based content; and adaptive delivery solutions for streaming video content in various bitrate streaming formats; content preparation and packaging for multiple platforms, a customizable media player, and content protection technologies; a suite of analytics tools to monitor online video viewer experiences and the effectiveness of Web software downloads, while measuring audience engagement, and quality of service performance; and NetStorage, a cloud storage solution.


This article is published by The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.